Clinical Trial

Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC

Study acronym: CHANCE2421
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 14, 2025 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based efficacy is unclear. This study aimed to evaluate whether extrahepatic LNM is associated with worse survival outcomes as compared to other metastatic sites in patients with advanced HCC.
Trial Details
NCT Number NCT06876753
Lead Sponsor Zhongda Hospital
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 300 participants
Start Date 2018-06-01
Primary Completion 2025-06-01 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-14